文献速递淋巴瘤

儿童与青少年间变性大细胞淋巴瘤

Anaplastic large cell lymphoma in children and adolescents.
PubMed 文献 · Br J Haematol · 2025-05-12

儿童与青少年间变性大细胞淋巴瘤(ALCL)中超过95%为ALK阳性,其发病基于组成性活跃的ALK激酶信号。不同化疗方案长期无事件生存率相似,约70%;复发患者采用不同再诱导和巩固方案总生存率接近95%。2010年代报道微小播散病和残留病、组织学亚型及抗ALK抗体滴度为显著独立预后因素,近15年靶向治疗(维布妥昔单抗、ALK抑制剂)显示高效低毒。

要点

  • 儿童与青少年ALCL中超过95%为ALK阳性。
  • 不同化疗方案长期无事件生存率相似,约70%,与药物、剂量和疗程无关。
  • 复发患者采用不同再诱导和巩固方案总生存率接近95%。

核心结论

  • ALK阳性ALCL的未来方向是通过开发「无化疗」方案明确靶向治疗在标准风险患者中的作用,并采用整合方法治愈高风险患者。

研究设计与样本

  • 综述,检索范围与样本量原文未报告。

主要发现

  • 不同化疗方案导致长期无事件生存率惊人地相似,为70%,与药物、剂量和疗程无关。
  • 复发ALCL患者采用非常不同的再诱导和巩固方法治疗成功,总生存率接近95%。
  • 2010年代,微小播散病和残留病、组织学亚型及抗ALK抗体滴度被报道为显著独立预后因素。
  • 过去15年,靶向治疗(维布妥昔单抗、ALK抑制剂)已证明高效低毒。

关键数值与推荐

  • ALK阳性ALCL占儿童和青少年ALCL病例的>95%。
  • 不同化疗方案的长期无事件生存率为70%。
  • 复发ALCL患者经不同再诱导和巩固方案治疗的总生存率接近95%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma (ALCL) accounts for >95% of ALCL cases in children and adolescents. The first description of ALCL as a CD30-positive lymphoma in 1985 was followed by the detection of chromosomal translocations involving the ALK gene at chromosome 2p23. The pathogenesis of ALK-positive ALCL is based on signalling from the constitutive active ALK kinase. The clinical characteristics, therapy regimens and outcome data were reported in the 1990s and 2000s. Different chemotherapy regimens led to astonishingly similar long-term event-free survival rates of 70%, independent of the drugs, doses and duration of therapy. Additionally, patients with relapsed ALCL are treated successfully with very different re-induction and consolidation approaches leading to an overall survival approaching 95%. In the 2010s, minimal disseminated and residual disease, histological subtype and antibody titres against ALK were reported as significant independent prognostic factors. Over the last 15 years, targeted therapies (brentuximab vedotin, ALK inhibitors) have demonstrated high efficacy with low toxicity. The future of ALK-positive ALCL is to define the role of targeted therapies by developing a 'chemotherapy-free' approach for patients with standard-risk ALCL and an integrated approach to cure patients with high-risk ALCL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Lowe EJ, Woessmann W. Anaplastic large cell lymphoma in children and adolescents. Br J Haematol. 2025. PMID: 40351161. doi:10.1111/bjh.20154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。